(Q36490533)

14 August 2017

In vitro activities of tigecycline against the Bacteroides fragilis group (English)

1 reference

14 August 2017

Bacteroides fragilis

1 reference

N V Jacobus

1

1 reference

14 August 2017

L A McDermott

series ordinal

2

1 reference

14 August 2017

R Ruthazer

series ordinal

3

1 reference

14 August 2017

D R Snydman

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Antimicrobial Agents and Chemotherapy

14 August 2017

1 reference

14 August 2017

48

1 reference

14 August 2017

3

1 reference

14 August 2017

1034-1036

1 reference

In vitro activities of newer quinolones against bacteroides group organisms

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353084

In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline

30 September 2017

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14982803

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1128/AAC.48.3.1034-1036.2004

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f4neygfigvgujbjtykvr4jzcyq

30 July 2022

release_f4neygfigvgujbjtykvr4jzcyq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f4neygfigvgujbjtykvr4jzcyq

30 July 2022

https://api.fatcat.wiki/v0/release/f4neygfigvgujbjtykvr4jzcyq

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/f4neygfigvgujbjtykvr4jzcyq

PubMed publication ID

1 reference

30 July 2022